A National Cancer Database analysis revealed racial and ethnic disparities in patients with gastric cancer in the use of preoperative chemotherapy and in outcomes.
A recent study found that a biosimilar provides improved outcomes without increased risk of toxicity for patients with DLBCL and treatment-induced neutropenia.
The US Preventive Services Task Force advises against ovarian cancer screening in asymptomatic women not known to be at high risk, concluding that the potential harms of screening outweigh the benefits.
Women who get magnetic resonance imaging screening tests for breast cancer are more likely to get invasive surgical biopsies to look for tumors than women who just get screening mammograms.
A study presented at the ASCO Cancer Survivorship Symposium evaluated the impact of a breast cancer survivorship model on health system resources and costs.
Survival outcomes may be worse for patients with ALL living in intermediate and high socioeconomically deprived areas as well as for those treated in hospitals with lower volumes of patients.
The FDA has approved the first treatment for a type of localized prostate cancer, using a novel endpoint to support the approval.
The American Society of Clinical Oncology and the National Comprehensive Cancer Network have collaborated for the first time to release new clinical guidelines for managing immunotherapy-related toxicities.
Results of a study identified unmet support needs of survivors of cancer that could be addressed through improved care coordination at a comprehensive cancer center.
The ASCO Task Force assessed six national pathway vendors to compare their products against the ASCO criteria for high-quality clinical pathways.